CJC Peptide (CJC1295): GHRH Analog for GH Research
GH Secretagogue Research
Clinical Evidence
Last Updated: May 2026
CJC peptide — specifically CJC-1295 with Drug Affinity Complex (DAC) — is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered to extend serum half-life from minutes to days. Where native GHRH is cleaved by DPP-IV enzymes within 7 minutes of administration, the DAC modification allows CJC-1295 to bind reversibly to serum albumin, sustaining biological activity across a window of 6–8 days. Research into this compound focuses on its potential to maintain elevated GH and IGF-1 signalling in animal and human experimental models, often studied alongside GH secretagogues such as GHRP-2 and Ipamorelin to characterise the synergy between GHRH and ghrelin receptor pathways.
Key Takeaways
- CJC-1295+DAC extends native GHRH half-life from ~7 minutes to 6–8 days via albumin-binding Drug Affinity Complex chemistry
- Phase II clinical research (Teichman et al. 2006) recorded IGF-1 increases of 28–43% vs placebo over 8 weeks
- A single injection produced sustained, measurable GH elevation for up to 6 days in healthy adult subjects (Jette et al. 2005)
- CJC-1295 acts on GHRH receptors (GHRH-R) at the pituitary; it is mechanistically distinct from ghrelin-pathway secretagogues like GHRP-2 and Ipamorelin
- Sold strictly as a research chemical in the UK — not approved for human therapeutic use and not classified as a controlled substance
Research-Grade CJC-1295+DAC
99%+ purity, HPLC verified. Batch-specific COA available. UK-sourced, rapid dispatch.
What Is CJC Peptide? Understanding the GHRH Analog Class
The term “CJC peptide” refers to a family of synthetic growth hormone-releasing hormone analogues developed to overcome the principal limitation of endogenous GHRH: its extremely short half-life. Native GHRH(1-44) — the full-length endogenous hormone — is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other serum proteases, limiting its window of biological activity to approximately 7 minutes after systemic administration. This renders it impractical as a research tool for studying sustained GHRH-axis activation.
CJC-1295 specifically is a 30-amino-acid peptide corresponding to GHRH(1-29) with a C-terminal lysine that has been modified with a maleimide–biotin reactive group — the Drug Affinity Complex (DAC). The DAC linker enables the peptide to covalently bind to Cys34 of circulating serum albumin within seconds of administration, effectively hitching to albumin’s endogenous 19-day half-life in a slow-release depot. The GHRH peptide dissociates gradually, producing a prolonged, pulsatile GH signalling profile rather than a transient spike.
CJC-1295 Without DAC (Modified GRF 1-29)
Researchers should note that “CJC-1295 without DAC” — also labelled Modified GRF(1-29) or Mod GRF 1-29 — is a related but distinct compound. It retains the four amino-acid substitutions at positions 2, 8, 15, and 27 that confer DPP-IV resistance, extending half-life to approximately 30 minutes, but lacks the albumin-binding DAC linker. This produces a shorter, sharper GH pulse profile more analogous to endogenous GHRH release patterns. The two forms represent different pharmacokinetic research models rather than interchangeable compounds.
Mechanism of Action: How CJC-1295 Activates the GH Axis
CJC-1295 exerts its activity by binding to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. GHRH-R is a G-protein-coupled receptor (GPCR) coupled to Gs alpha subunits. Ligand binding activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream transcription factors — notably CREB (cAMP response element-binding protein) — and directly stimulates GH synthesis and release from secretory granules.
The resulting GH release is pulsatile in character, preserving the physiological oscillatory pattern of GH secretion rather than producing a sustained supraphysiological elevation. This is mechanistically important for researchers studying the downstream effects of GH axis activation: preserved pulsatility maintains sensitivity of peripheral GH receptors and IGF-1 liver production, whereas continuous non-pulsatile GH elevation can paradoxically produce receptor desensitisation.
GHRH-R vs GHS-R1a: Two Complementary Pathways
CJC-1295 acts exclusively on GHRH-R and does not interact with the ghrelin receptor (GHS-R1a). This distinguishes it mechanistically from GH secretagogues (GHS) such as GHRP-2 and Ipamorelin, which act on GHS-R1a. Research has consistently demonstrated that GHRH-R agonism and GHS-R1a agonism produce synergistic rather than additive GH release — the combination of both pathways in the same experiment typically produces GH amplitudes 3–10 times greater than either compound alone. This has made CJC-1295 a frequent pairing partner in GH axis research protocols alongside GHRP-class compounds.
An endocrinology research team studying age-related GH decline needed a compound capable of producing sustained GHRH-pathway stimulation without repeated daily administrations that could confound their data. CJC-1295+DAC’s week-long half-life made it the compound of choice — a single administration on day one produced measurable IGF-1 elevation across the full 8-week observation period, removing the pharmacokinetic variability of short-acting analogues from the dataset entirely.
Clinical Research: Key Studies on CJC-1295
The most significant published research on CJC-1295 comes from two studies by Jette et al. (2005) and Teichman et al. (2006), both published in peer-reviewed endocrinology journals, characterising pharmacokinetics, GH release patterns, and IGF-1 responses in healthy adult human subjects.
Jette et al. 2005 — Pharmacokinetics and GH Response
Jette and colleagues administered single doses of CJC-1295 to healthy subjects and characterised the resulting pharmacokinetic and pharmacodynamic profile. A single administration produced a statistically significant increase in mean GH concentration that persisted for approximately 6 days. Importantly, mean 24-hour GH concentrations were elevated throughout this period, confirming that the albumin-binding mechanism was producing sustained pulsatile release rather than a single transient peak. The study established the foundational pharmacokinetic model for CJC-1295+DAC research.
Teichman et al. 2006 — Phase II Dose-Response and IGF-1
Teichman and colleagues conducted an 8-week Phase II study assessing multiple dose levels of CJC-1295, measuring IGF-1 responses and tolerability across groups. Results showed IGF-1 increases of 28–43% relative to placebo across the tested dose range, with the response sustained across the full 8-week research period. The compound was well-tolerated, with adverse events comparable to placebo at lower dose levels. This study remains the primary human clinical evidence base for CJC-1295’s IGF-1 modulating activity.
GH Optimisation Research Stack
CJC-1295+DAC paired with GHRP-2 — the two-pathway GH axis research combination.
CJC-1295 vs Native GHRH: Comparative Research Profile
| Parameter | Native GHRH(1-44) | CJC-1295+DAC |
|---|---|---|
| Serum half-life | ~7 minutes | 6–8 days |
| DPP-IV resistance | None | High (4 substitutions) |
| Albumin binding | None | Covalent via DAC linker |
| Receptor target | GHRH-R | GHRH-R |
| IGF-1 elevation (human research) | Transient (~30 min) | Sustained; 28–43% vs placebo (8 weeks) |
| Research administration frequency | Multiple daily administrations | Once weekly (research protocols) |
Frequently Asked Questions
What is the difference between CJC peptide and GHRH?
CJC-1295 is a synthetic analogue of GHRH with modifications that dramatically extend its research utility. Native GHRH is degraded within ~7 minutes by serum enzymes, making sustained GH axis research impractical. CJC-1295+DAC binds to serum albumin via the DAC linker, extending its half-life to 6–8 days while retaining GHRH-R binding affinity. This makes it a preferred tool for long-duration GH axis research without frequent re-administration.
Is CJC-1295 the same as CJC-1295 without DAC?
No. CJC-1295+DAC and CJC-1295 without DAC (Mod GRF 1-29) share the same amino-acid backbone but differ critically in pharmacokinetics. The DAC linker in CJC-1295+DAC enables albumin binding, producing a 6–8 day half-life. Without the DAC, the compound’s DPP-IV-resistant modifications extend the half-life to approximately 30 minutes — still significantly longer than native GHRH but producing a distinctly different GH release profile. Researchers should specify which form is under study.
Why is CJC-1295 often researched alongside GHRP-2 or Ipamorelin?
CJC-1295 acts on GHRH-R (GHRH receptor), while GHRP-2 and Ipamorelin act on GHS-R1a (ghrelin receptor). These two receptor pathways produce synergistic GH release — published research demonstrates that co-activation produces GH amplitudes substantially greater than either compound alone. The combination allows researchers to study maximal GHRH-axis activation while characterising pathway interactions. The GH Optimization Research Stack is formulated specifically for this dual-pathway research model.
What does the Drug Affinity Complex (DAC) do?
The DAC is a maleimide-PEG linker attached to the C-terminal lysine of CJC-1295. Upon systemic administration, the maleimide group reacts rapidly with the free thiol of Cys34 on serum albumin, forming a stable thioether bond. This covalent attachment leverages albumin’s naturally long serum half-life (~19 days), slowly releasing the active GHRH peptide as the bond hydrolyses over 6–8 days. The result is a pharmacokinetic profile fundamentally different from unmodified peptides.
Is CJC-1295 legal to purchase in the UK?
CJC-1295+DAC is not listed as a controlled substance under the Misuse of Drugs Act 1971 and does not fall under Psychoactive Substances Act 2016 enforcement for research chemical suppliers. It is available for purchase in the UK as a research chemical for laboratory and scientific research purposes only. It is not MHRA-approved for human therapeutic use and must not be used for human consumption.
What purity and testing standards should researchers look for?
Research-grade CJC-1295 should be verified to a minimum of 98% purity by HPLC, with a batch-specific COA confirming compound identity by LC-MS, purity percentage, test date, batch number, analytical method, and laboratory name. Generic template COAs without batch numbers are a red flag. Pure Grade Labs CJC-1295+DAC is verified to 99%+ purity with a batch-specific HPLC COA available for every order.
Source Research-Grade CJC-1295+DAC
10MG vials. 99%+ purity. Batch COA. UK-based. Crypto and bank transfer accepted.
Summary
CJC peptide — specifically CJC-1295+DAC — represents the current benchmark for GHRH-analogue research, solving the native hormone’s core limitation of rapid enzymatic degradation. The DAC albumin-binding mechanism extends serum half-life from 7 minutes to 6–8 days, enabling week-long sustained GH axis stimulation from a single administration. Phase II clinical research has confirmed statistically significant IGF-1 increases of 28–43% versus placebo sustained over 8 weeks, with a tolerability profile comparable to placebo at tested doses.
The mechanistic complementarity between CJC-1295 and GHS-R1a agonists such as GHRP-2 and Ipamorelin makes CJC-1295 a central compound in two-pathway GH axis research, with the dual-pathway model producing substantially amplified GH responses compared to either compound alone. This synergy has positioned the GHRH analog + GHS combination as the standard model for studying pituitary GH axis dynamics in preclinical and early clinical research settings.
In the UK, CJC-1295+DAC is available as a research chemical and is not subject to controlled substance restrictions, making it accessible to qualified researchers studying GH axis physiology, IGF-1 signalling, and related endocrine mechanisms.
References
- Jette L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: a potential long-lasting GRF analog. Endocrinology. 146(7):3052–3058. DOI: 10.1210/en.2004-1609
- Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 91(3):799–805. DOI: 10.1210/jc.2005-1536
- Freda PU. (2009). Monitoring of acromegaly: what should be measured? Growth Hormone & IGF Research. 19(3):167–175.
- Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 54(12):1316–1329.
- Alba M, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism. 291(6):E1290–E1294.